For the first time, artificial intelligence developed by DeepMind, one of the world’s premier AI labs, has been used to significantly advance scientific research. The project, known as AlphaFold, uses AI to predict the configuration of a protein. With an estimated 10300 configurations, the task is highly complex. In addition, this week we highlight ... READ MORE >
Health Care
From hospital systems to home care providers, the health care sector is replete with middle market companies. The health needs of an aging population assure that this industry will continue to grow in coming years.
5 things to know in life sciences: Week of September 27
Telehealth has been one of the big developments in health care brought on by the COVID-19 pandemic. It both promises to make care easier for patients to fit into their busy lives and holds the potential of allowing trials and new treatments to reach people far from the research hospitals in city centers. However, there are hurdles to overcome before much of ... READ MORE >
5 things to know in life sciences: Week of September 20
As the delta variant ravages communities throughout the Unites States, it is important to look past the data and remember that every infection, hospitalization and death leaves an indelible mark on that patient’s family and community. And few communities have suffered as much as Black communities in the South. This week we look at this tragedy—and the ... READ MORE >
5 things to know in life sciences: Week of September 13
This week we explore promising developments in CRISPR genome editing, also known as clustered regularly interspaced short palindromic repeats, a bacterial defense system. We also look at two of the latest U.S. Food and Drug Administration’s approvals, including another one for a surgical robot that leverages artificial intelligence and a nerve stimulation ... READ MORE >
5 things to know in life sciences: Week of September 6
As the threat of the delta variant continues to mount, the Biden administration has released plans to extend its vaccine mandate to U.S. companies. Affecting over 80 million U.S. workers, we expect there to be significant conversation on this topic in the coming months. This week, we also dig into Pfizer’s impressive team of “variant hunters” who work around ... READ MORE >
5 things to know in life sciences: Week of August 23
We often hear about rare and orphan diseases and think they must be, well, rare. For every individual rare disease, that is true. But when considered together, a surprising number of people are affected by one of the thousands of known rare diseases. This week we share two stories of how big data and machine learning are being used to better identify and ... READ MORE >
5 things to know in life sciences: Week of August 16
With the school year starting and office reopening plans shifting, many people are unsure of what activities they should be comfortable doing and what they should avoid in the face of the delta variant. Instead of asking experts what other people should do, this week we look at what decisions those experts are making for themselves. We also look at the ... READ MORE >
5 things to know in life sciences: Week of August 9
With eyes on infrastructure policymaking this week, our roundup takes a look at the components of the Democrats' $3.5 trillion budget framework that could affect the life sciences industry. We also highlight a major investment in surgical robotics, the performance of companies post-merger with a special purpose acquisition company and share which of the ... READ MORE >
5 things to know in life sciences: Week of August 2
This week we start with a look at the potential for gene and cell therapy to radically change health care over the coming decade. Although there are few approved drugs using these technologies today, the pipeline of candidates in all phases of clinical studies is full of potential cell and gene therapy treatments. We also highlight recent life sciences ... READ MORE >
5 things to know in life sciences: Week of July 26
This week we highlight the United States Food and Drug Administration’s approval of an insulin biosimilar and their granting of its status as interchangeable with the name brand drug. This promises significant savings for diabetic patients who often face financial hardships because of the cost of care. We also look at an artificial intelligence tool for ... READ MORE >